Assess the Pharmacokinetics of Rosuvastatin and Simvastatin when administered alone or in combination with Fostamatinib - Statin DDI

Study identifier:D4300C00039

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An Open-label, Non-randomized, 2-Period, Fixed Sequence, Single-center Study to Assess the Pharmacokinetics of Rosuvastatin and Simvastatin in Healthy Subjects when Administered Alone and in Combination with Fostamatinib 100 mg Twice Daily

Medical condition

Rheumatoid Arthritis

Phase

Phase 1

Healthy volunteers

Yes

Study drug

Fostamatinib, Rosuvastatin, Simvastatin

Sex

All

Actual Enrollment

42

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 01 Nov 2012
Primary Completion Date: 01 Jan 2013
Study Completion Date: 01 Jan 2013

Study design

Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science

Verification:

Verified 01 Jan 2014 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria